Imagia

Canexia Health, Inc. specializes in genomic-based molecular diagnostics for oncology, providing oncologists with essential tools to inform treatment decisions. The company offers a range of solutions, including Find It, which identifies somatic mutations in tumors to guide treatment; Follow It, an invasive biopsy option for monitoring cancer progression and assessing treatment resistance; and Fusions, an assay that isolates and analyzes relevant genetic fusions. Additionally, Canexia Health provides an informatics platform that integrates clinical and genomic data, enhancing the accuracy of cancer diagnosis and treatment planning. Founded in 2012 and based in Vancouver, Canada, Canexia Health was formerly known as Contextual Genomics Inc. before rebranding in July 2020. Through its clinically-validated tests and partnerships with laboratories, the company aims to improve patient outcomes by enabling more effective treatment options and interventions early in the disease management process.

Cadens Medical Imaging specializes in the development of innovative medical imaging software aimed at enhancing cancer care. The company has created FDA and CE cleared products that utilize AI-based technologies to improve the analysis and interpretation of diagnostic images. By integrating 2D and 3D imaging capabilities, Cadens' solutions allow healthcare professionals to capture more accurate diagnostic images while maintaining user-friendly ergonomics. As an ISO 13485 certified organization, Cadens is committed to delivering patient benefits through its unique foundational technologies and intellectual property, which facilitate collaborative biomarker discovery across various healthcare institutions.